Adaptimmune Therapeutics
Manufacturing · United Kingdom · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
60 Jubilee Ave Milton Park, Abingdon, Ox...Phone Number
+44 1235430000Website
www.adaptimmune.comRevenue
$65.1 MillionStock Symbol
ADAPIndustry
ZI Rank: 2
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
3
3
1
1
1
2
About Adaptimmune Therapeutics
Established in 2008, Adaptimmune LLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary T-cell receptor platform in the treatment of cancer. Headquarters is located in Philadelphia, Pennsylvania.Explore more
Adaptimmune Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Adaptimmune Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Adaptimmune Therapeutics has new funding data
Adaptimmune Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Adaptimmune Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Adaptimmune Therapeutics recently announced quarterly report
Click to see if Adaptimmune Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Adaptimmune Therapeutics
Check out if Adaptimmune Therapeutics is spiking on competitors!
Check if Adaptimmune Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Adaptimmune Therapeutics
Compare insights from companies similar to Adaptimmune Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Adaptimmune Therapeutics
$65.1M
501-1,000
Public
$485.9M
2008
MS
Mark StielowVice President, Manufacturing & Technical Operations (US)
Company Profile Activity
Activity Insights
Adaptimmune Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Adaptimmune Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Adaptimmune Therapeutics.
Adaptimmune Therapeutics financials insights
Gather financial insights about Adaptimmune Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Grant
$2.6M
Series A
$104M
2015
Stock Offering
$191.3M
2017
Stock Offering
$62M
Stock Offering
$42M
2020
Stock Offering
$84M
Adaptimmune Therapeutics Tech Stack
A closer look at the technologies used by Adaptimmune Therapeutics
See more technologies
Most Recent Scoops
Left Company
Executive Move
Adrian (Ad) Rawcliffe, Chief Executive Officer, has recently left the organization and now serves as Chief Executive Officer, Etiome & Chief Executive Officer, Partner Flagship Pioneering for Etiome.
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
Person-Based
Person-Based
Adaptimmune Therapeutics News & Media
Helen Tayton-Martin Named CEO of Evaxion Biotech Amid Leadership Changes in Biotech Sector
Helen Tayton-Martin, co-founder of Adaptimmune, has bee […]US WorldMeds Completes Acquisition of Adaptimmune's Cell-Therapy Portfolio; Ensures Continued Patient Access to Tecelra and Advances Development of lete-cel
LOUISVILLE, Ky., Aug. 4, 2025 /PRNewswire/ -- US WorldMeds (USWM) reported the successful closing of the previously announced acquisition of Adaptimmune Therapeutics plc's (Adaptimmune) cell–therapy assets—including TECELRA® (afamitresgene autoleucel), lete–cel, afami–cel, and uza–cel....Adaptimmune sells 4 cell therapies to pharma for $55M, plans layoffs - Fierce Biotech
After months of searching for strategic options, Adaptimmune is offloading its cell therapies to a global pharma, which plans to offer jobs to about half of the biotech’s employees. | After months of searching for strategic options, Adaptimmune is offloading its cell therapies to a global pharma, which plans to offer jobs to about half of the biotech’s employees. Once the deal closes, Adaptimmune will reduce its remaining workforce by 62%.Adaptimmune Raises 'Substantial Doubt' About Business Despite First-in-Class T Cell Therapy
Adaptimmune is rolling out its T cell therapy Tecelra for synovial sarcoma, recording $1.2 million in sales since its approval in August 2024. Nevertheless, it is pausing development of two oncology assets to save money.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Adaptimmune Therapeutics
Sign Up For FreeTo access detailed company insights
Established in 2008, Adaptimmune LLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary T-cell receptor platform in the treatment of cancer. Headquarters is located in Philadelphia, Pennsylvania.... Read More
